Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

TEL AVIV, Israel, April 28, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it has signed a binding term-sheet with Entomus s.r.o. for a license agreement for the development and commercialization of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation that allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.). A definitive agreement determining, among other things, the milestones payments and future royalty payments is to be executed within ninety (90) days.

Read more at prnewswire.com